Skip to main content

Table 2 Likelihood of receiving a prolactin test: proportional hazards regression results

From: Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study

  Hazard ratio 95% CI p Value
Antipsychotic categories vs other typicals (excluded category):    
Risperidone (yes = 1) 1.341 1.085 to 1.658 0.0067
Clozapine (yes = 1) 0.748 0.411 to 1.362 0.3418
Olanzapine (yes = 1) 0.948 0.788 to 1.229 0.8894
Quetiapine (yes = 1) 0.927 0.738 to 1.164 0.5124
Ziprasidone (yes = 1) 1.162 0.857 to 1.576 0.3343
Haloperidol (yes = 1) 0.852 0.609 to 1.319 0.3523
Perphenazine (yes = 1) 0.741 0.416 to 1.319 0.3077
Prolactin-related symptoms prior to event or censoring (yes = 1)* 6.736 5.080 to 8.932 < 0.0001
Interaction of antipsychotic and PPAE:    
Risperidone × PPAEs 1.406 1.040 to 1.901 0.0269
Clozapine × PPAEs 1.340 0.617 to 2.911 0.4594
Olanzapine × PPAEs 1.156 0.838 to 1.593 0.3771
Quetiapine × PPAEs 0.936 0.673 to 1.302 0.6929
Ziprasidone × PPAEs 1.068 0.686 to 1.663 0.7710
Haloperidol × PPAEs 1.094 0.676 to 1.770 0.7134
Perphenazine × PPAEs 1.608 0.747 to 3.463 0.3077
Age 0.962 0.959 to 0.964 < 0.0001
Male gender 0.329 0.300 to 0.361 < 0.0001
Used another antipsychotic within 6 months prior to treatment (yes = 1) 1.070 0.984 to 1.164 0.1130
Concurrent use of other atypical antipsychotic, ratio of days supply to index antipsychotic days supply 1.647 1.465 to 1.852 < 0.0001
Concurrent use of other typical antipsychotic, ratio of days supply to index antipsychotic days supply 1.136 0.954 to 1.354 0.1531
Diagnosis:    
Schizophrenia (yes = 1) 1.009 0.925 to 1.101 0.8352
Affective psychosis (yes = 1) 1.318 1.212 to 1.434 < 0.0001
Other psychosis (yes = 1) 0.953 0.879 to 1.032 0.2370
Other non-psychotic mental disorder (yes = 1) 1.266 1.143 to 1.402 < 0.0001
Health coverage vs fee-for-service (excluded category):    
Medicaid (yes = 1) 0.924 0.830 to 1.028 0.1474
HMO (yes = 1) 1.146 1.016 to 1.293 0.0266
  1. Number of observations with event: 2,796; number of observations censored: 195,130.
  2. *Gynecomastia, galactorrhea, oligomenorrhea, amenorrhea, dysmenorrhea, hypogonadism, hypothyroidism, infertility-male-hypospermatogenesis, infertility-female-pituitary/hypothalamic, impotence-organic, psychosexual dysfunction, genitourinary malfunctions arising from mental factors, and alopecia.
  3. CI, confidence interval; HMO, health maintenance organization; PPAEs, potentially prolactin-related adverse events.